Skip to search formSkip to main content

177Lu-PSMA-617

Known as: 177Lu-617-prostate-specific membrane antigen ligand 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DipeptidesHeterocyclic Compounds, 1-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
PurposeRadioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
AimOur aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer
BACKGROUND Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
PurposeRadioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2017
2017
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3.
INTRODUCTION Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2016
2016
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
PurposeThe purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies.
AIM The prostate-specific membrane antigen (PSMA) is a cell surface protein, which is overexpressed in nearly all cases of… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
PurposeDosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?